Advertisement

Digestive Diseases and Sciences

, Volume 59, Issue 2, pp 242–258 | Cite as

Measures to Reduce Mother-to-Child Transmission of Hepatitis B Virus in China: A Meta-Analysis

  • Hua Xu
  • Teng Zeng
  • Jun-Ying Liu
  • Yu Lei
  • Shan Zhong
  • Yun-Jian Sheng
  • Zhi Zhou
  • Hong Ren
Review

Abstract

Background

Mother-to-child transmission (MTCT) is the main mode of spread of hepatitis B virus (HBV) in China. We performed a meta-analysis to compare the effects of three measures for prevention of MTCT.

Methods

A meta-analysis was performed on randomized controlled trials and non-randomized studies comparing the index of MTCT among five groups of pregnant women: hepatitis B immunoglobulin (HBIG) administration, antiviral treatment, placebo, elective caesarean section, and vaginal delivery.

Results

Compared with the control group, the incidence of HBV intrauterine infection (RR = 0.42, 95 % CI 0.27–0.64, P < 0.0001) and the number of chronic hepatitis B (CHB) infants (RR = 0.44, 95 % CI 0.32–0.61, P < 0.00001) were lower in the HBIG administration group. In the antiviral treatment group, serum HBV DNA levels were lower (MD = −4.01, 95 % CI −5.07 to −2.94, P < 0.00001) at the time of delivery, and normalization of ALT levels was better (RR = 1.11, 95 % CI 1.06–1.17, P < 0.0001). Infant serum HBsAg positivity (RR = 0.45, 95 % CI 0.22–0.91, P = 0.03) and incidence of infant HBV transmission RR = 0.06, 95 % CI 0.01–0.24, P < 0.0001) were reduced in antiviral the treatment group. Infant serum anti-HBs positivity at birth (RR = 1.24, 95 % CI 0.89–1.74, P = 0.2) or at 6–7 months (RR = 0.98, 95 % CI 0.86–1.11, P = 0.73) was not significantly different between the caesarean section and vaginal delivery groups. The incidence of infant CHB infection may have been higher in the vaginal delivery group (RR = 2.20, 95 % CI 1.02–4.74, P = 0.04).

Conclusions

Administration of HBIG or antiviral therapy to HBV carrier mothers during pregnancy is effective in reducing MTCT.

Keywords

Hepatitis B virus Mother-to-child transmission Reduce Meta-analysis 

Notes

Acknowledgments

Zhi Zhou conceived the study, provided funding support, and revised the manuscript critically for important intellectual content. Hua Xu made substantial contributions to the design of the study and to acquisition, analysis, and interpretation of the data. Teng Zeng, Jun-Ying Liu, Yu Lei, Shan Zhong, Yun-Jian Sheng, and Hong Ren participated in the design of the study and in acquisition, analysis, and interpretation of data. All authors read and approved the final manuscript. This work was supported by National Nature Science Foundation of China (grant numbers 81171563 and 31000397).

Conflict of interest

None.

Supplementary material

10620_2013_2918_MOESM1_ESM.doc (60 kb)
Supplementary material 1 (DOC 60 kb)

References

  1. 1.
    Edmunds WJ, Medley GF, Nokes DJ, O’Callaghan CJ, Whittle HC, Hall AJ. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect. 1996;117:313–325.PubMedCrossRefGoogle Scholar
  2. 2.
    Tran TT. Management of hepatitis B in pregnancy: weighing the options. Clevel Clin J Med. 2009;76:S25–S29.CrossRefGoogle Scholar
  3. 3.
    Kim SS, Cheong JY, Cho SW. Current nucleos(t)ide analogue therapy for chronic hepatitis B. Gut Liver. 2011;5:278–287.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: epidemiology and prevention in developing countries. World J Hepatol. 2012;4:74–80.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Degli Esposti S, Shah D. Hepatitis B in pregnancy: challenges and treatment. Gastroenterol Clin North Am. 2011;40:355–372.PubMedCrossRefGoogle Scholar
  6. 6.
    Zhang SL, Yue YF, Bai GQ, Shi L, Jiang H. Mechanism of intrauterine infection of hepatitis B virus. World J Gastroenterol. 2004;10:437–438.PubMedGoogle Scholar
  7. 7.
    Bai H, Zhang L, Ma L, Dou XG, Feng GH, Zhao GZ. Relationship of hepatitis B virus infection of placental barrier and hepatitis B virus intra-uterine transmission mechanism. World J Gastroenterol. 2007;13:3625–3630.PubMedGoogle Scholar
  8. 8.
    Xu DZ, Yan YP, Choi BC, et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol. 2002;67:20–26.PubMedCrossRefGoogle Scholar
  9. 9.
    Yogeswaran K, Fung SK. Chronic hepatitis B in pregnancy: unique challenges and opportunities. Korean J Hepatol. 2011;17:1–8.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Yang J, Zeng XM, Men YL, Zhao LS. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus—a systematic review. Virol J. 2008;5:100.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Kumar A. Hepatitis B: virus infection and pregnancy: a practical approach. Indian J Gastroenterol. 2012;31:43–54.PubMedCrossRefGoogle Scholar
  12. 12.
    Deng M, Zhou X, Gao S, et al. The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. Virol J. 2012;9:185.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Li XM, Shi MF, Yang YB, et al. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol. 2004;10:3215–3217.PubMedGoogle Scholar
  14. 14.
    Zhu Q, Yu G, Yu H, et al. A randomized control trial on interruption of HBV transmission in uterus. Chin Med J. 2003;116:685–687.PubMedGoogle Scholar
  15. 15.
    Borgia G, Carleo MA, Gaeta GB, Gentile I. Hepatitis B in pregnancy. World J Gastroenterol. 2012;18:4677–4683.PubMedCrossRefGoogle Scholar
  16. 16.
    Han L, Zhang HW, Xie JX, Zhang Q, Wang HY, Cao GW. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol. 2011;17:4321–4333.PubMedCrossRefGoogle Scholar
  17. 17.
    Lin HH, Kao JH, Hsu HY, Mizokami M, Hirano K, Chen DS. Least microtransfusion from mother to fetus in elective cesarean delivery. Obstet Gynecol. 1996;87:244–248.PubMedCrossRefGoogle Scholar
  18. 18.
    Wang J, Zhu Q, Zhang X. Effect of delivery mode on maternal-infant transmission of hepatitis B virus by immunoprophylaxis. Chin Med J. 2002;115:1510–1512.PubMedGoogle Scholar
  19. 19.
    Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care. 1996;12:195–208.PubMedCrossRefGoogle Scholar
  20. 20.
    Ryu HJ, Lee JM, Ahn SH, et al. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol. 2010;82:1835–1842.PubMedCrossRefGoogle Scholar
  21. 21.
    Qiu YW, Jiang XH, Huang LH, et al. A study on the treatment of chronic hepatitis B with YMDD mutation. Chin J Hepatol. 2009;17:171–174.Google Scholar
  22. 22.
    Sheng YJ, Liu JY, Tong SW, et al. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J. 2011;8:393.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Yuan J, Lin J, Xu A, et al. Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single-centre randomized study. J Viral Hepat. 2006;13:597–604.PubMedCrossRefGoogle Scholar
  24. 24.
    Li XM, Yang YB, Hou HY, et al. Interruption of HBV intrauterine transmission: a clinical study. World J Gastroenterol. 2003;9:1501–1503.PubMedGoogle Scholar
  25. 25.
    Xu Q, Xiao L, Lu XB, Zhang YX, Cai X. A randomized controlled clinical trial: interruption of intrauterine transmission of hepatitis B virus infection with HBIG. World J Gastroenterol. 2006;12:3434–3437.PubMedGoogle Scholar
  26. 26.
    Yue Y, Yang X, Zhang S. Prevention of intrauterine infection by hepatitis B virus with hepatitis B immune globulin: efficacy and mechanism. Chin Med J. 1999;112:37–39.PubMedGoogle Scholar
  27. 27.
    Zhu Q, Lu Q, Gu X, Xu H, Duan S. A preliminary study on interruption of HBV transmission in uterus. Chin Med J. 1997;110:145–147.PubMedGoogle Scholar
  28. 28.
    Wang FY, Lin P, Zhang HZ. A randomized controlled trial on effect of hepatitis B immune globulin in preventing hepatitis B virus transmission from mothers to infants. Chin J Pediatr. 2008;46:61–63.Google Scholar
  29. 29.
    Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16:94–103.PubMedCrossRefGoogle Scholar
  30. 30.
    Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55:1215–1221.PubMedCrossRefGoogle Scholar
  31. 31.
    Su GG, Pan KH, Zhao NF, Fang SH, Yang DH, Zhou Y. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol. 2004;10:910–912.PubMedGoogle Scholar
  32. 32.
    Pan CQ, Han GR, Jiang HX, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10:520–526.PubMedCrossRefGoogle Scholar
  33. 33.
    Yu M, Jiang Q, Ji Y, et al. The efficacy and safety of antiviral therapy with lamivudine to stop the vertical transmission of hepatitis B virus. Eur J Clin Microbiol Infect Dis. 2012;31:2211–2218.PubMedCrossRefGoogle Scholar
  34. 34.
    Zang L-J, Wang L. Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients. Chin J Hepatol. 2009;17:561–563.Google Scholar
  35. 35.
    Han G-R, Jiang H-X, Wang G-J, et al. Efficacy and safety of telbivudine in pregnant women to prevent perinatal transmission of hepatitis B virus. Chin J Hepatol. 2012;20:201–205.Google Scholar
  36. 36.
    Chen H, Ren J, Liu X-H. Influence of different delivery patterns on mother-to-child vertical transmission of HBV. Chin J Woman Child Health Res. 2008;19:214–216.Google Scholar
  37. 37.
    Huang L. Research about the efficacy of delivery mode on maternal-infant transmission of hepatitis B virus. New Med. 2012;43:247–249.Google Scholar
  38. 38.
    Fan W. Effect of delivery mode on maternal-infant transmission of hepatitis B Virus. Guangdong Med J. 2007;28:252–253.Google Scholar
  39. 39.
    Gu J. Effect of delivery mode on maternal-infant transmission of hepatitis B virus. Ningxia Med J. 2006;28:858–859.Google Scholar
  40. 40.
    Zhang Q. Effect of delivery mode on maternal-infant transmission of hepatitis B virus. Chin J Clin Med. 2009;16:570–571.Google Scholar
  41. 41.
    Zhang S. Effect of delivery and interruption mode on maternal-infant transmission of hepatitis B virus. Mod Prev Med. 2006;33:72–74.Google Scholar
  42. 42.
    Cai S. Discuss on relative factors of maternal-infant vertical transmission of hepatitis B virus. Mod Diagn Treat. 2009;20:23–24.Google Scholar
  43. 43.
    Liu H. Relevant research of delivery mode on maternal-infant transmission of hepatitis B virus. Chin J Mod Drug Appl. 2009;3:30–31.Google Scholar
  44. 44.
    Bzowej NH. Optimal management of the hepatitis B patient who desires pregnancy or is pregnant. Curr Hepat Rep. 2012;11:82–89.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Yue Y. Clinical study on the prevention of HBV from mother to infant by injection of HBIG in pregnant women with HBsAg. Chin J Pract Gynecol Obstet. 1999;15:547–548.Google Scholar
  46. 46.
    Xiao XM, Li AZ, Chen X, Zhu YK, Miao J. Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy. Int J Gynaecol Obstet. 2007;96:167–170.PubMedCrossRefGoogle Scholar
  47. 47.
    Han ZH, Zhong LH, Wang J, et al. The impact of antepartum injection of hepatitis B immunoglobulin on maternal serum HBV DNA and anti-HBs in the newborns. Chin J Internal Med. 2007;46:376–378.Google Scholar
  48. 48.
    Shi Z, Li X, Ma L, Yang Y. Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother-to-child transmission-a meta-analysis. Int J Infect Dis. 2010;14:e622–e634.PubMedCrossRefGoogle Scholar
  49. 49.
    Zhang RL, Luo Y, Xie JX, et al. A correlation analysis between the rate of vertical transmission of HBV and HBsAg-positive father to infant and the rate of neonatal cord blood HBV-DNA. Chin J Epidemiol. 2010;31:159–162.Google Scholar
  50. 50.
    Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315–1341. quiz 1286.PubMedCrossRefGoogle Scholar
  51. 51.
    Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a update. Hep Intl. 2008;2008:263–283.CrossRefGoogle Scholar
  52. 52.
    Munderi P, Helen Wilkes H, Tumukunde D. Pregnancy rates and outcomes among women on triple-drug antiretroviral therapy in the DART trial [Poster WEPEB261]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa; 2009.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Hua Xu
    • 1
  • Teng Zeng
    • 1
    • 2
  • Jun-Ying Liu
    • 1
    • 3
  • Yu Lei
    • 1
    • 2
  • Shan Zhong
    • 1
    • 2
  • Yun-Jian Sheng
    • 1
    • 2
  • Zhi Zhou
    • 1
    • 2
  • Hong Ren
    • 1
    • 2
  1. 1.The Second College of Clinical MedicineThe Second Affiliated Hospital of Chongqing Medical UniversityChongqingChina
  2. 2.Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of EducationSecond Affiliated Hospital of Chongqing Medical UniversityChongqingChina
  3. 3.Department of the Digestive SystemZhou Kou Central HospitalZhoukouChina

Personalised recommendations